In October 2016, Galychpharm, a part of Arterium Corporation, passed assessment by the Belarusian GMP inspectorate.

Design of the packaging for Casark — one of Arterium's* heart disease drugs — has been updated. Casark H and Casark HD, fixed combination dosage forms of the product, are already sold in new packs. Starting March, 8 mg, 16 mg, and 32 mg mono forms will be available in new design too.

Arterium Corporation has launched a new product in the Ukrainian market—Mediatorn, a neurological drug. Mediatorn's active agent ipidacrine hydrochloride stimulates propagation of nerve impulses in the central and peripheral nervous system.

The Arterium Corporation virtual tour now includes the infusion pharmaceuticals production facility—the brand new and the largest in terms of floor space production line at Galychpharm. In May 2016, the line, which currently makes Ornizol, Floxium, Linezolidin, Sodium chloride, Glucose, and other similar products, was certified as GMP-compliant.

Recently, Ministry of Health of the Republic of Belarus has enacted a resolution, which enables Belarusian regulating authorities to inspect foreign pharmaceutical companies for compliance with the good manufacturing practice (GMP) requirements.

A new sports ground was installed in Bohdan Khmelnytsky Central Recreation Park in Lviv. Complete with universal sports equipment, it is a great place to do sports for adults and children alike.